Journal of Clinical Endocrinology & Metabolism, Vol 80, 2709-2714, Copyright © 1995 by Endocrine Society

ARTICLES

Effects of estrogen exposure and reproductive factors on bone mineral density and osteoporotic fractures

TV Nguyen, G Jones, PN Sambrook, CP White, PJ Kelly and JA Eisman
Bone and Mineral Research Division, St. Vincent's Hospital, Sydney, New South Wales, Australia.

The risk of osteoporotic fracture is related to peak bone mass achieved at skeletal maturity and subsequent bone loss. Although premature menopause is a risk factor for osteoporosis, the effect of exposure to endogenous estrogen during a woman's reproductive years is poorly characterized. We analyzed the relationship between reproductive factors and estrogen exposure on bone mineral density (BMD) and incidence of atraumatic fracture in data from 1091 women (age: 70 +/- 7.2 yr; mean +/- SD) participating in the Dubbo Osteoporosis Epidemiology Study. Age- and weight-adjusted BMD among women who had used estrogen replacement therapy (ERT) for more than 5 yr was higher at the lumbar spine and femoral neck by 13.7% and 10.2% (P < 0.001), respectively, compared with women who had used ERT for less than 5 yr or nonusers. Duration of exposure to estrogen (years of menstruation plus postmenopausal ERT use) was associated with higher BMD, such that BMD increased by 2-3% for every 10-yr increase in years of estrogen exposure; thus women who menstruated for more than 40 yr had a 6-8% higher BMD than did women who menstruated for less than 30 yr. Higher BMD was also significantly associated with high parity, such that nulliparous women had 5-6% lower BMD than did their peers of the same age and weight. The incidence of atraumatic fractures among non-ERT users was higher than that of ERT-users [odds ratio (OR): 1.06; 95% confidence interval (CI): 0.94-1.16] and was significantly lower among parous women than among nulliparous women (OR 0.94; 95% CI: 0.84-0.98) in univariate analysis. Longer duration of menstruation was associated with lower fracture incidence (OR for 1 SD = 6.6 yr: 0.93; 95% CI: 0.86- 1.02). Moreover, when all of these factors were considered simultaneously, parity remained a significant determinant of fracture as well as femoral neck BMD. We conclude that high parity and longer duration of exposure to estrogen, either through natural menstruation or postmenopausal ERT, have protective effects on BMD and are associated with a reduced incidence of atraumatic fracture in a population-based study.

This article has been cited by other articles:

				T. Chevalley, J.-P. Bonjour, S. Ferrari, and R. Rizzoli Influence of Age at Menarche on Forearm Bone Microstructure in Healthy Young Women J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2594 - 2601. [Abstract] [Full Text] [PDF]

				J.-P. Bonjour and T. Chevalley Pubertal Timing, Peak Bone Mass and Fragility Fracture Risk IBMS BoneKEy, February 1, 2007; 4(2): 30 - 48. [Abstract] [Full Text] [PDF]

				H. B. Nichols, A. Trentham-Dietz, J. M. Hampton, L. Titus-Ernstoff, K. M. Egan, W. C. Willett, and P. A. Newcomb From Menarche to Menopause: Trends among US Women Born from 1912 to 1969 Am. J. Epidemiol., November 15, 2006; 164(10): 1003 - 1011. [Abstract] [Full Text] [PDF]

				E. A. Streeten, K. A. Ryan, D. J. McBride, T. I. Pollin, A. R. Shuldiner, and B. D. Mitchell The Relationship between Parity and Bone Mineral Density in Women Characterized by a Homogeneous Lifestyle and High Parity J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4536 - 4541. [Abstract] [Full Text] [PDF]

				Z. S. Tan, S. Seshadri, A. Beiser, Y. Zhang, D. Felson, M. T. Hannan, R. Au, P. A. Wolf, and D. P. Kiel Bone Mineral Density and the Risk of Alzheimer Disease Arch Neurol, January 1, 2005; 62(1): 107 - 111. [Abstract] [Full Text] [PDF]

				M. L.C. Hagemans, Y. T. van der Schouw, M. J.J. de Kleijn, W. A. van Staveren, V. J.M. Pop, G. L. Leusink, and D. E. Grobbee Indicators for the total duration of premenopausal endogenous estrogen exposure in relation to BMD Hum. Reprod., September 1, 2004; 19(9): 2163 - 2169. [Abstract] [Full Text] [PDF]

				S. Palomba, F. Orio Jr., A. Colao, C. di Carlo, T. Sena, G. Lombardi, F. Zullo, and P. Mastrantonio Effect of Estrogen Replacement Plus Low-Dose Alendronate Treatment on Bone Density in Surgically Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1502 - 1508. [Abstract] [Full Text] [PDF]

				J. A. Eisman Pharmacogenetics of the Vitamin D Receptor and Osteoporosis Drug Metab. Dispos., April 1, 2001; 29(4): 505 - 512. [Abstract] [Full Text]

				C. L. CARLSON, M. CUSHMAN, P. L. ENRIGHT, J. A. CAULEY, and A. B. NEWMAN Hormone Replacement Therapy Is Associated with Higher FEV1 in Elderly Women Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 423 - 428. [Abstract] [Full Text]

				K. K. Nicodemus, A. R. Folsom, and K. E. Anderson Menstrual History and Risk of Hip Fractures in Postmenopausal Women The Iowa Women's Health Study Am. J. Epidemiol., February 1, 2001; 153(3): 251 - 255. [Abstract] [Full Text] [PDF]

				J. A. Eisman Genetics of Osteoporosis Endocr. Rev., December 1, 1999; 20(6): 788 - 804. [Abstract] [Full Text]